ICM
SRPT icon

Ionic Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Ionic Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,920
Closed -$270K – 307
2020
Q3 		$270K Buy
+1,920
New +$292K 0.02% 168

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ionic Capital Management's SRPT Position: Q4 2020 in Review

Ionic Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2020, closing a stake of 1,920 shares — an estimated $270K sold.

Ionic Capital Management first reported a position in SRPT in Q3 2020 and held it in 1 quarter. The position peaked at $270K in Q3 2020. 454 funds tracked by Wall St. Rank hold SRPT as of Q4 2020.

  • Ionic Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Ionic Capital Management sold 1,920 Sarepta Therapeutics shares in Q4 2020, an estimated $270K.
  • Ionic Capital Management first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 1 quarter.
  • Ionic Capital Management's Sarepta Therapeutics position peaked at $270K in Q3 2020.
  • 454 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2020.

Based on Ionic Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.